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Abstract: Oropharyngeal and esophageal dysmotility can cause serious clinical complications such as
aspiration pneumonia, cachexia, and sarcopenia, with a resulting increase in mortality and disability.
The current standard of care for the treatment of SSc-associated swallowing dysfunction is mainly
supportive, although severe cases are usually refractory to conventional management. Recent studies
have shown that the abnormal production of functional autoantibodies such as anti-cholinergic muscarinic receptor III antibodies may participate in the pathogenesis of SSc-associated gastrointestinal
dysmotility and may provide a novel target for therapeutic intervention. We describe two patients
with severe and rapid onset of SSc-associated severe swallowing dysfunction and esophageal dysmotility who had failed standard of care therapy, requiring complete enteral and parenteral nutrition.
Both patients were positive for the presence of circulating antimuscarinic III receptor antibodies.
They were treated with IVIG at a dose of 2 g/Kg/month divided in two consecutive days, for six
months. Following IVIG therapy, both patients markedly improved their symptoms as shown by a
reduction in their UCLA2.0 score, and achieved an improvement of esophageal motility documented
radiologically. Both patients resumed oral feeding and had their feeding tubes removed within the
treatment period. None of the patients developed severe adverse events attributable to IVIG, except
for low-grade fever during IVIG infusion in one of the cases. These results provide support for the
role of functional autoantibodies in the development of SSc-associated gastrointestinal dysfunction.
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1. Introduction
Systemic Sclerosis (SSc) is a systemic autoimmune disease characterized by prominent
fibrosis of the skin and internal organs, vasculopathy, and cellular and humoral abnormalities. These phenomena occur sequentially or simultaneously in different organs causing
organ dysfunction and failure. The vast majority of patients with SSc develop esophageal
dysmotility that is characterized by ineffective peristalsis and low resting pressure of
the lower esophageal sphincter (LES) [1–4]. Subsequent gastro-esophageal reflux disease
(GERD) is common, affecting up to 80% of SSc patients, and is often complicated by the
development of esophagitis, esophageal strictures, Barrett’s esophagus, and esophageal
cancer [5–8]. Severe esophageal dysmotility is also strongly associated with the development of oropharyngeal dysmotility and swallowing dysfunction resulting in subsequent
complications including aspiration pneumonia, cachexia, and sarcopenia.
The current treatment of esophageal dysmotility includes the use of proton pump
inhibitors (PPIs) and promotility agents, as well as procedures such as endoscopic dilation
of esophageal strictures [9–11]. On the other hand, patients with severe swallowing dysfunction require enteral nutrition or total parenteral nutrition (TPN) to provide adequate
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nutrition and avoid aspiration of esophageal or gastric content into the lungs [7]. Recently,
it has been proposed that the abnormal production of auto-antibodies against muscarinic
receptor 3 may contribute to the pathogenesis of GI dysmotility in SSc [12–16]. These autoantibodies have been found to cause antibody-mediated attenuation of smooth-muscle
contraction in animal models [12]. Furthermore, it has been demonstrated in ex vivo studies, that the addition of pooled human Immunoglobulin G (IgG) was able to neutralize the
effects of SSc autoantibodies and prevented antimuscarinic receptor-mediated reduction
in smooth muscle contraction [15,16]. Based on the results of these in vitro and in vivo
studies, Intravenous Immunoglobulins (IVIG) have been proposed as a potential agent for
the treatment of SSc-associated GI dysmotility. Inhibition of T cell activation, complement
pathway, and the blockade of the Fcγ receptor by IVIG have been also proposed to play
a potential role in SSc. Here, we describe our experience with two SSc patients with SSc
presenting with acute onset of severe GI dysmotility and swallowing dysfunction that was
successfully treated with IVIG.
2. Patients and Methods
Two patients fulfilling the 2013 American College of Rheumatology/European League
Against Rheumatism (ACR/EULAR) criteria for SSc [17] without myositis, presented
with recent onset of severe swallowing dysfunction and esophageal dysmotility, poorly
responsive to currently recommended medical therapy that included PPIs, H2 blockers
and prokinetic agents. The clinical features of these patients are summarized in Table 1.
The patients were treated with IVIG in addition to standard therapy. The patients did not
have any history of anaphylaxis or severe adverse reactions to human blood and blood
products or any history of a recent deep vein thrombosis or stroke. The potential risks and
benefits of IVIG therapy were extensively discussed with the patients, and informed consent
was provided by each patient. High-resolution esophageal manometry was performed
before initiation of IVIG treatment. The severity of GI symptoms was quantified pre-and
post-treatment by the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract
Instrument Version 2 (UCLA2.0) [18]. All the data underlying this article are available
in the article. Individual patient consent for publication was obtained and patients were
provided with a copy of this manuscript.
Table 1. Clinical Features of SSc patients prior to IVIG treatment.
Patient 1

Clinical Features

Patient 2

1-Age/Sex

50/Male

72/Female

2-Skin Thickening
distribution/mRSS

Diffuse, involving trunk and
proximal upper and lower
extremities/mRSS of 25

Limited, involving fingers and
face/mRSS of 3

3-Raynaud’s

Started 8 months prior to
presentation

Started 10 years prior to
presentation

4-Calcinosis

Not present

Not present

5-Interstitial lung disease

Nonspecific interstitial
pneumonia on HRCT

Not present on HRCT

6-Pulmonary arterial hypertension

Not present per ECHO, right
heart catheterization

Not present per ECHO

7-ANA titer and pattern

1:1280, speckled pattern

1:640, anti-centromere pattern

8-Myositis Antibody panel *

Negative

Negative

9-Scleroderma specific antibodies
(a)
Anti Topoisomerase Ab
(b) Anti RNA Polymerase III Ab
(c)
Anti Centromere Ab

(a)
(b)
(c)

(a)
(b)
(c)

Negative
Positive
Negative

Negative
Negative
Positive

Positive at 1.86 ng/mL (test
Positive at 1.57 ng/mL (test
range 0.312–20 ng/mL)
range 0.312–20 ng/mL)
Abbreviations: mRSS: modified Rodnan Skin Score, HRCT: High Resolution Computed Tomography, ANA: Anti
Nuclear Antibody. * Anti-PM/Sci-100 Ab; Anti-MDA5 Ab (CADM-140); Anti-NXP-2 Ab; Anti-TIF-1gamma Ab;
Anti-SAE1 Ab, IgG; Anti-SRP Ab; Anti-U3 RNP; Anti-U2 RNP Ab; Anti-Mi-2 Ab; Anti-PL-7 Ab; Anti-PL-12 Ab;
Anti-EJ Ab; Anti-OJ Ab; Anti-Ku Ab; Anti-Jo-1 Ab; Anti-U1 RNP Ab; Anti-SS-A 52kD Ab.
10-Anti-muscarinic receptor 3 Ab
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3. Results
3.1. Patient 1
A 50-year-old male with a past medical history of moderate mitral valve prolapse and
a recent diagnosis of coronary artery disease (CAD) developed symptoms of Raynaud’s
phenomenon a few months before the onset of rapidly progressive diffuse skin thickening
and progressive dyspnea on exertion. He was found to have a positive ANA (1:1280) with a
speckled pattern, a high titer of RNA Polymerase III antibody, and negative anti-centromere
and anti-topoisomerase antibodies. The patient was diagnosed with rapidly progressive
diffuse cutaneous SSc at another hospital and received treatment with mycophenolate
mofetil with very poor gastrointestinal tolerance.
At the initial evaluation at Thomas Jefferson University Scleroderma Center, the
patient had seven months since the first noticeable occurrence of skin thickening and
complained of dyspnea on exertion, painful joint contractures. The patient also developed
and severe dysphagia and swallowing dysfunction, nausea, regurgitation, and frequent
post-prandial vomiting causing a very low caloric intake of less than 400 calories/day
leading to severe weight loss. These symptoms persisted despite of use of proton pump
inhibitors (PPIs). Prokinetics were not tolerated. Physical examination disclosed severe
weight loss (greater than 100 pounds or approximately 50% of his normal weight), marked
diffuse skin thickening with proximal limb and trunk involvement, and a modified Rodnan
Skin Score (mRSS) of 25. Multiple joint contractures and tendon friction rubs were evident
on musculoskeletal exam. Auscultation of the chest disclosed bibasilar crackles and a
mitral valve click sound. The abdomen was distended but not tender with normal bowel
sounds. Additional testing showed severe lung restriction at Pulmonary Function Tests
(FVC 25% of the predicted value with unobtainable DLCO despite repetitive testing). A
high-resolution computerized tomography of the chest showed reticulonodular opacities
with few bronchiectasis and a patulous esophagus. An echocardiogram demonstrated a
low ejection fraction (EF 35%) without regional wall motion abnormalities, nor evidence of
pulmonary hypertension. Right and left heart catheterization displayed normal pulmonary
artery pressures and resistance, and CAD. Laboratory tests showed anemia, elevated inflammatory markers (CRP, ESR, and Ferritin), normal creatine kinase (39 IU/L), and a
negative myositis autoantibody panel. Furthermore, electromyography (EMG) did not
show evidence of myopathy or neuropathy. Owing to the severity of GI dysmotility, an
enzyme-linked immune-sorbent assay for anti-muscarinic receptor 3 antibodies (Aviva, San
Diego, CA, USA) was performed finding positive results with a concentration calculated at
1.86 ng/mL (test range 0.312–20 ng/mL). High-resolution esophageal manometry demonstrated absent contractility of the esophagus without any measurable contraction of the
esophageal body during any swallow and normal resting pressure of the LES (27.3 mmHg).
Upper esophageal sphincter (UES) resting pressure and relaxation were normal as well pharyngeal peristalsis was preserved. In addition, upper endoscopy did not show macroscopic
or microscopic evidence of eosinophilic esophagitis.
The patient failed to improve swallowing or recover esophageal functionality following esophageal sphincter dilation and was not able to tolerate institution of oral intake.
He was started on TPN and gastric-jejunal enteral feeding. The patient was then treated
with parenteral cyclophosphamide (750 mg/m2 ) monthly administration for SSc-associated
interstitial lung disease for six months in addition to a small dose of prednisone (5 mg/d)
that was started prior to the onset of GI symptoms for the control of joint pain. Owing to
the severity of the GI involvement and the presence of antimuscarinic antibodies in the
serum and following informed consent the patient was treated with IVIG (1 g/Kg/dose)
for 2 consecutive days every month for 5 months (see Figure 1A) of a total of 6 planned
infusions (the patient declined the last infusion given his remarkable improvement) with no
adverse events. Following six months of therapy with cyclophosphamide and IVIG, the patient improved the skin sclerotic changes with a reduction of mRSS to 15 and improvement
of lung volumes. Furthermore, a combination of TPN, iron infusions, and low-volume
tube feeding was used to maintain appropriate nutrition. With clinical improvement the
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patient was progressively changed to oral intake, achieving complete oral caloric requirements 6 months following initiation of IVIG. His UCLA 2.0 GI score markedly improved
from 1.75 to 0.175. He was switched from cyclophosphamide to oral mycophenolate with
good GI tolerance and stopped IVIG after 6 months without recurrence of symptoms.
He regained 80 pounds of weight and he was able to re-initiate his physical exercising
J. Clin. Med. 2022, 11, x FOR PEER REVIEW
5 of 9
activities. However, high-resolution esophageal manometry following treatment failed to
demonstrate any evidence of esophageal peristalsis improvement.

A

B
Figure 1. Evolution of weight, nutritional therapy, additional immunosuppressive therapy, and
IVIG over one year. This figure shows patients’ weight trend (black line) over time in relation to IVIG
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3.2. Patient 2
A 72-year-old female with a past medical history of iron deficiency anemia secondary
to intestinal angiodysplasia, Raynaud’s phenomenon for 10 years, and GERD for 13 years
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3.2. Patient 2
A 72-year-old female with a past medical history of iron deficiency anemia secondary
to intestinal angiodysplasia, Raynaud’s phenomenon for 10 years, and GERD for 13 years
treated with PPIs, was hospitalized with a sudden onset of fever, shortness of breath,
cough, severe dysphagia, and possible aspiration pneumonia following a plastic surgical
procedure (Rhytidectomy). She was initially treated with parenteral antibiotics and hydration. Following antibiotic therapy, the patient became afebrile but complained of dyspnea
on exertion and severe dysphagia. A physical exam was remarkable for the inability to
swallow her saliva, the presence of crackles in the right lung base and a normal abdominal
exam. She had sclerodactyly and facial skin thickening with a mRSS of 3. Few telangiectasias in palms were noticed. The patient lacked sicca signs or symptoms suggestive of
Sjogren’s syndrome. Laboratory tests showed mild anemia with a hemoglobin level of
9 g/dL and a positive serum ANA test at a 1:640 titer with an anti-centromere antibody
pattern. Serum inflammatory markers and muscle enzymes and creatinine kinase level
were normal. Myositis antibody panel was negative as well as no evident neuromuscular
abnormality was found at EMG. The presence of anti-muscarinic receptor 3 antibodies
was demonstrated by enzyme-linked immune-sorbent assay (Aviva, San Diego, CA, USA)
and its concentration was calculated at 1.57 ng/mL (range 0.312–20 ng/mL). A chest
computed tomography disclosed ground glass opacities in the right lower lung field and
endo-bronchial material in airways compatible with aspiration pneumonia. An echocardiogram did not show evidence of increased pulmonary artery pressure. High-resolution
esophageal manometry demonstrated absent contractility of the esophagus without any
scorable contraction during any swallow. Upper esophageal sphincter (UES) resting pressure was low (20 mmHg) with normal pharyngeal peristalsis. Upper endoscopy did not
show evidence of eosinophilic esophagitis. A fluoroscopic swallow study displayed mildly
delayed oral transit and laryngeal penetration. Pulmonary function tests performed following pneumonia recovery showed normal lung volumes (FVC 97% of predicted) and a mild
decline in diffusion capacity (DLCO 60% of predicted).
A gastric tube was placed and enteral nutrition was initiated. Following informed
consent, she was started on IVIG 1 g/kg/day for 2 consecutive days every month with
no adverse events except for low-grade fever post-administration. Over the subsequent
several months, the patient regained her ability to swallow and successfully transitioned
from enteral nutrition to oral nutrition 4 months following IVIG therapy initiation. Timing
of these clinical events and therapy are summarized in Figure 1B. Her UCLA 2.0 GI score improved from 0.88 to 0.075. She completed 6 months IVIG infusion therapy. High-resolution
esophageal manometry failed to demonstrate improvement of esophageal peristalsis, but a
video swallow study showed marked improvement and normalization in the swallowing
function with resolution of tracheal aspiration.
4. Discussion
Severe swallowing dysfunction in SSc patients is not only associated with increased
mortality but also is frequently refractory to conventional therapy, requiring prolonged
enteral and parenteral nutrition [11]. Recent studies have shown that functional antimuscarinic M3-R receptor autoantibodies present in the serum of certain SSc and Sjogren’s
disease patients are capable of blocking gastrointestinal smooth muscle contraction in vivo
and this can be reversed with pooled human IgG by neutralizing these circulating autoantibodies [13–16]. The hypothesis of imbalance of the stimulatory-inhibitory balance of
the enteric nervous system caused by M3-R blocking antibodies is illustrated in Figure 2.
Furthermore, it has been suggested that immune-mediated mechanisms may play a role in
the development of a wider spectrum of gastrointestinal dysmotility in idiopathic gastroparesis and paraneoplastic disorders, and the term autoimmune-mediated gastrointestinal
dysmotility (AGID) has been coined to refer to gastrointestinal dysfunction caused by
functional auto-antibodies, disorders of Cajal cells, and local or systemic inflammatory
disorders [19,20]. Following this hypothesis, illustrated in Figure 2, a series of patients with
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refractory and idiopathic gastroparesis have been treated with IVIG with highly encouraging results, showing improvement in nausea, vomiting, early satiety, and abdominal
pain [19]. In addition, in another recent retrospective review, patients with generalized
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(A). IVIG, blocks the abnormal auto-antibodies, helping to restore the altered equilibrium and to
recover normal motility (B). ACh: acetylcholine, VIP: vasoactive intestinal peptide; NO: nitric oxide.
recover normal motility (B). ACh: acetylcholine, VIP: vasoactive intestinal peptide; NO: nitric oxide.
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It is important to emphasize that the selection of patients with very early and acute
GI severe dysmotility, likely occurring prior to structural myogenic damage, can also explain the dramatic improvement of function observed in the patients described here. In
addition, none of these patients had associated myositis, a condition associated with GI
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It is important to emphasize that the selection of patients with very early and acute
GI severe dysmotility, likely occurring prior to structural myogenic damage, can also
explain the dramatic improvement of function observed in the patients described here.
In addition, none of these patients had associated myositis, a condition associated with
GI dysmotility and swallowing dysfunction that can be improved by the use of IVIG. We
fully recognize that the concomitant use of cyclophosphamide immunosuppression for
the rapidly progressive skin and ILD may be considered a confounding factor in the first
patient but rapid improvement of swallowing function is not commonly observed neither
in SSc patients treated with cyclophosphamide nor as a natural evolution of the disease.
Furthermore, in a large inception cohort of SSc Canadian and Australian patients, the
risk of developing severe gastrointestinal involvement was not modified by exposure to
immunosuppression [24]. Although no specific analysis of the cases with swallowing
dysfunction was made in this study, the data support our clinical observations. We are
also very aware that pilot studies and case series with small number of patients are not
intended to evaluate the efficacy or safety of a specific therapeutic intervention. However,
we are convinced that they are useful to help understanding the pathophysiology and
management of rare diseases and to support the initiation of larger controlled studies.
This report, with a markedly positive outcome, encourages the performance of more
extensive and randomized controlled trials for evaluating the potentially beneficial effects
of IVIG administration in SSc patients with new onset of severe swallowing dysfunction.
In addition, in this pilot experience, high-resolution esophageal manometry proved not to
be useful to quantify the clinically significant improvement, suggesting the need to explore
other methods with greater sensitivity to quantify the change in esophageal function.
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